References
- Babu, R. J., Kanikkannan, N., Kikwai, L., Ortega, C., Andega, S., Ball, K., Yim, S., & Singh, M. (2003). The influence of various methods of cold storage of skin on the permeation of melatonin and nimesulide. Journal of Controlled Release, 86, 49–57., [PUBMED], [INFOTRIEVE], [CSA]
- Barry, B. W. (2001). Novel mechanisms and devices to enable successful transdermal drug delivery. European Journal of Pharmaceutical Sciences, 14, 101–114., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gondaliya, D., & Pundarikakshudu, K. (2003). Studies in formulation and pharmacotechnical evaluation of controlled release transdermal delivery system of bupropion. AAPS PharmSciTech, 4(1). , Article 3. [CSA], [CROSSREF]
- Hertzsch, J. (1984). n-Propyl-TDHL (Protergurid), ein neuer hochwirksamer Dopaminagonist, Wirkung und Kinetik am Menschen [n-Propyl-TDHL (Proterguride), a new and highly potent dopamine receptor agonist, effects and kinetics in human volunteers]. In: MD Thesis. Berlin: Free University.
- Kim, J.-H., & Choi, H.-K. (2002). Effect of additives on the crystallization and the permeation of ketoprofen from adhesive matrix. International Journal of Pharmaceutics, 236, 81–85., [PUBMED], [INFOTRIEVE], [CSA]
- Kim, J.-H., Lee, C. H., & Choi, H.-K. (2002). Transdermal delivery of physostigmine: effects of enhancers and pressure-sensitive adhesives. Drug Development and Industrial Pharmacy, 28(7), 833–839., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Krause, W., & Hümpel, M. (1988). Pharmacokinetics of Proterguride in rat and cynomolgus monkey. Xenobiotica, 18(1), 41–48., [PUBMED], [INFOTRIEVE]
- Lipp, R., & Müller-Fahrnow, A. (1999). Use of X-ray crystallography fort he characterization of single crystals grown in steroid containing transdermal drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics, 47, 133–138., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Metman, L., Gillespie, M., Farmer, C., Bibbiani, F., Konitsiotis, S., Morris, M., Shill, H., Bara-Jimenez, W., Maral Mouradian, M., & Chase, T. (2001). Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clinical Neuropharmacology, 24(3), 163–169., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Naik, A., Kalia, Y. N., & Guy, R. H. (2000). Transdermal drug delivery: overcoming the skin's barrier function. Pharmaceutical Science & Technology Today, 3, 318–326., [INFOTRIEVE], [CROSSREF]
- Prausnitz, M. R., Mitragotri, S., & Langer, R. (2004). Current status and future potential of transdermal drug delivery. Nature Reviews, Drug Discovery, 3, 115–124., [CROSSREF]
- Roy, S. D., Gutierrez, M., Flynn, G. L., & Cleary, G. W. (1996). Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design. Journal of Pharmaceutical Sciences, 85(5), 491–495., [PUBMED], [INFOTRIEVE], [CROSSREF]
- Stocchi, F. (2003). Prevention and treatment of motor fluctuations. Parkinsonism & Related Disorders, 9, 73–81., [INFOTRIEVE], [CROSSREF]
- Wachtel, H. (1983). Central dopaminergic and antidopaminergic effects of ergot derivatives structurally related to lisuride. In: D. B. Calne, R. Horowski, R. J. McDonald, & W. Wuttke (Eds.), Lisuride and Other Dopamine Agonists. New York: Raven Press, 109–125.
- Yum, S. I. (1989). Transdermal therapeutic systems and rate controlled drug delivery. Medical Progress Through Technology, 15, 47–52., [PUBMED], [INFOTRIEVE]
- Zimmermann, I. (1983). Determination of pKa values from solubility data. International Journal of Pharmaceutics, 13, 57–65., [CROSSREF]